Zolgensma's $2.125 million sticker price is not the number Medicaid actually pays. Ten states now pay a $212,500-a-year annuity instead, and that structure, not the WAC, is what any second gene therapy in SMA will be measured against.
Onasemnogene abeparvovec (Zolgensma) lists at $2.125 million for a single infusion, the reference price every SMA access conversation starts from. But list price is not transaction price for a widening share of the market. Ten state Medicaid programs have enrolled in the Centers for Medicare & Medicaid Services' Cell and Gene Therapy Access (CGTA) model, which converts the one-time list price into a milestone-linked annuity of roughly $212,500 a year for ten years, contingent on the child sustaining motor-function gains under annual review. That structure, negotiated once and now replicated, is the actual price precedent the market has set, and it is the number any future SMA gene therapy, including a possible attenuation booster, will be priced against, not the $2.125 million headline.
The two chronic therapies price on an entirely different axis. Nusinersen (Spinraza) costs roughly $750,000 in year one (four loading doses) and about $375,000 a year in maintenance thereafter; risdiplam (Evrysdi) runs about $340,000 a year, weight-based, for life. Benefit routing then compounds the comparison: nusinersen, physician-administered by intrathecal injection, routes to Medicare Part B with minimal patient cost-sharing for dual-eligible beneficiaries, while oral risdiplam routes to Part D, exposing patients to coinsurance that can exceed what the intrathecal route costs them out of pocket. Over a ten-year horizon, cumulative nusinersen or risdiplam spend approaches the CGTA annuity's nominal total, so the pricing argument payers actually run is time-value and risk-adjusted, not sticker-price comparison, and it is the model any new entrant, chronic or gene therapy, must replicate before a single formulary conversation starts.
US SMA pricing — CGTA annuity vs one-time WAC and chronic-therapy comparators
| Agent | Payment Structure | List/Annualized Price | Benefit Routing |
|---|---|---|---|
| Zolgensma (onasemnogene abeparvovec) | One-time WAC or 10-state CGTA annuity | $2.125M one-time; or $212,500/yr x10yr under CGTA | Case-by-case; Medicaid outcomes-based |
| Spinraza (nusinersen) | Standard WAC, chronic | ~$750K yr1; ~$375K/yr maintenance | Medicare Part B (intrathecal) |
| Evrysdi (risdiplam) | Standard WAC, chronic | ~$340K/yr (weight-based) | Medicare Part D (oral) |
Sources: CMS CGTA SMA pilot enrollment data 2024; Novartis 2019 pricing disclosure; Biogen and Roche pricing disclosures; CMS Part B/Part D benefit-routing classifications.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- CGTA payment mechanics ($212,500/yr x10yr)
- milestone/continuation criteria
- the pricing precedent this sets for any second gene therapy, including a Zolgensma-attenuation booster
Delivers
- Part B vs Part D routing mechanics
- patient OOP comparison
- benefit-design implications for a new chronic or oral entrant
Delivers
- 10-year cost model: CGTA annuity total vs cumulative nusinersen/risdiplam spend
- break-even sensitivity
- the actual argument payers run internally
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why the CGTA annuity, not the $2.125M WAC, is the real Zolgensma price precedent
- Pressure-tested against nusinersen and risdiplam chronic-cost baselines before the rest of the model is built out
- How the 10-state CGTA milestone annuity converts list price into a risk-adjusted payment stream
- Where this structure sets the ceiling for any future SMA gene therapy
- Nusinersen's Part B routing vs risdiplam's Part D routing
- The patient OOP asymmetry this creates independent of net price
- Nusinersen and risdiplam cost trajectories as the comparator set
- What the analogue set implies for a new entrant's defensible price
- ICER's 2019 SMA cost-effectiveness framing
- Where cumulative chronic-therapy cost meets the CGTA annuity total
- The WAC, rebate, and milestone-payment components decomposed line by line
- The discount depth already observed in the CGTA precedent
- Sequencing recommendation across the Zolgensma-attenuation and other segment openings
- Conservative, base, and aggressive revenue scenarios tied to CGTA-style contracting
- The open pricing questions your team must close before a US SMA launch price is locked
- Structured for an internal pricing committee session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model is built from primary regulatory and payer sources (CMS, Novartis, Biogen, Roche pricing disclosures, ICER) and live outcomes-based-contracting documentation, not secondary summaries. Findings are independently verified before inclusion.
SMA US pricing sources: CMS CGTA SMA pilot enrollment data 2024, Novartis 2019 Zolgensma pricing and outcomes-based Medicaid contract disclosure, Biogen and Roche nusinersen/risdiplam pricing disclosures, and the ICER 2019 SMA Final Evidence Report.
- CGTA annuity structure and 10-state enrollment verified against CMS CGTA SMA pilot enrollment data 2024
- Zolgensma WAC and outcomes-based Medicaid contract terms verified against Novartis 2019 pricing disclosure
- Nusinersen and risdiplam pricing verified against Biogen and Roche pricing disclosures and Part B/Part D routing classifications
Frequently asked questions
Commission this model
AXLRx delivers US SMA pricing strategy models built for market access and pricing teams navigating CGTA outcomes-based contracting and Part B/D routing dynamics. Custom model in 72 hours.
Specify your indication, market basket, and comparator scope.
AXLRx analyst confirms pricing mechanism assumptions and WTP threshold before building.
Research-verified pricing model in 72 hours with optional analyst readout.